A novel obesity treatment drug targeting glucagon-like peptide-1/glucagon/glucose-dependent insulinotropic polypeptide receptor:retatrutide
Obesity is a complex disease characterized by excess adiposity caused by genetic and environmental factors.As a glucagon-like peptide-1 receptor/glucagon/glucose-dependent insulinotropic polypeptide receptor agonist,retatrutide(research code:LY3437943)has demonstrated long-term efficacy in the treatments of obesity and cardiovascular disease.The results of phase Ⅰ and Ⅱ clinical trials showed that retatrutide had good efficacy and safety profiles.This drug is currently in the recruit-ment phase of phase Ⅲ clinical trials.This article provides an overview of the retatrutide's basic information,mechanism of ac-tion,pre-clinical studies and clinical studies.
NETL
NSTL
万方数据
